| 2019冠状病毒病(COVID-19)重型、危重型患者用药管理经验 |
| |
| 引用本文： | 姜赛平,李璐,茹仁萍,张春红,饶跃峰,林彬,王融溶,陈娜,王小娟,蔡洪流,盛吉芳,周建英,卢晓阳,裘云庆.2019冠状病毒病(COVID-19)重型、危重型患者用药管理经验[J].浙江大学学报(医学版),2020,49(2):158-169. |
| |
| 作者姓名： | 姜赛平 李璐 茹仁萍 张春红 饶跃峰 林彬 王融溶 陈娜 王小娟 蔡洪流 盛吉芳 周建英 卢晓阳 裘云庆 |
| |
| 作者单位： | 1. 浙江大学医学院附属第一医院, 浙江 杭州 3100032. 杭州西溪医院, 浙江 杭州 3100233. 温州医科大学附属第一医院, 浙江 温州 3250004. 浙江大学医学院附属第二医院长兴院区, 浙江 长兴 313100 |
| |
| 摘 要： | 2019冠状病毒病（COVID-19）重型、危重型患者往往合并基础疾病，用药种类复杂，存在潜在的药物相互作用、特殊人群用药等问题。本文依据《新型冠状病毒肺炎诊疗方案（试行第六版）》，基于《2019冠状病毒病（COVID-19）诊疗浙江经验》，总结重型、危重型患者选择抗病毒药物、糖皮质激素、血管活性药物、抗菌药物、微生态制剂、营养支持方案等经验，建议针对药物疗效和疗程评估、药物不良反应防治、潜在药物相互作用识别、基于生物安全防护的个体化用药监测以及特殊人群给药等进行重点用药管理，以期为COVID-19患者临床药物选择和用药管理提供参考。
|
| 关 键 词： | 2019冠状病毒病 严重急性呼吸综合征冠状病毒2 新型冠状病毒感染 危重病 安全管理 药物利用 |
| 收稿时间： | 2020-02-23 |
Pharmaceutical care for severe and critically ill patients with COVID-19 |
| |
| JIANG Saiping,LI Lu,RU Renping,ZHANG Chunhong,RAO Yuefeng,LIN Bin,WANG Rongrong,CHEN Na,WANG Xiaojuan,CAI Hongliu,SHENG Jifang,ZHOU Jianying,LU Xiaoyang,QIU Yunqing.Pharmaceutical care for severe and critically ill patients with COVID-19[J].Journal of Zhejiang University(Medical Sciences),2020,49(2):158-169. |
| |
| Authors: | JIANG Saiping LI Lu RU Renping ZHANG Chunhong RAO Yuefeng LIN Bin WANG Rongrong CHEN Na WANG Xiaojuan CAI Hongliu SHENG Jifang ZHOU Jianying LU Xiaoyang QIU Yunqing |
| |
| Affiliation: | 1. The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China2. Hangzhou Xixi Hospital, Hangzhou 310023, China3. The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325000, China4. Changxing Hospital, the Second Affiliated Hospital, Zhejiang University School of Medicine, Changxing 313100, Zhejiang Province, China |
| |
| Abstract: | Severe and critically ill patients with coronavirus disease 2019 (COVID-19) were usually with underlying diseases, which led to the problems of complicated drug use, potential drug-drug interactions and medication errors in special patients. Based on Diagnosis and treatment of novel coronavirus pneumonia (trial version 6), and Management of COVID-19: the Zhejiang experience, we summarized the experience in the use of antiviral drugs, corticosteroids, vascular active drugs, antibacterial, probiotics, nutrition support schemes in severe and critically ill COVID-19 patients. It is also suggested to focus on medication management for evaluation of drug efficacy and duration of treatment, prevention and treatment of adverse drug reactions, identification of potential drug-drug interactions, individualized medication monitoring based on biosafety protection, and medication administration for special patients. |
| |
| Keywords: | Coronavirus disease 2019 Severe acute respiratory syndrome coronavirus 2 Novel coronavirus infection Critical illness Safety management Drug utilization |
|
| 点击此处可从《浙江大学学报(医学版)》浏览原始摘要信息 |
|
点击此处可从《浙江大学学报(医学版)》下载全文 |
|
